Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833130 · ClinicalTrials.gov registry record · Phase 4
Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT01833130 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 52 participants.
The verdict
NCT01833130, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
Interventions
- BIOLOGICAL OnabotulinumtoxinA
- DRUG Normal saline (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833130
The ClinicalTrials.gov registry entry for NCT01833130 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which OnabotulinumtoxinA is the first listed.
NCT01833130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833130 about?
NCT01833130 is a clinical study titled "Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)". This study will evaluate the use of the Assessment of Chronic Migraine Impacts (ACM-I) Questionnaire in assessing the impact and benefit of treatment with onabotulinumtoxinA (BOTOX®) in adults with chronic migraine.
What is the current status of trial NCT01833130?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2013-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01833130?
The interventions under investigation include: OnabotulinumtoxinA (BIOLOGICAL), Normal saline (placebo) (DRUG).
Who is sponsoring clinical trial NCT01833130?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.